Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
This article was originally published in PharmAsia News
Executive Summary
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.